Title	Completion Rate of Adjuvant Chemotherapy
Number of Patients Screened	28
Number of Patients Enrolled	28
Number of Patients Evaluable for Toxicity	28
Number of Patients Evaluated for Efficacy	28
Outcome Notes	Among the 28 patients, 20 (71.4%: 95% confidence interval, 53.6–89.3%) completed the protocol treatment. Because of toxicity, capecitabine was reduced in 10 cases (36%) and discontinued in 5 cases (19%), whereas oxaliplatin was reduced in 8 cases (29%) and discontinued in 8 cases (29%). The mean relative dose intensity of capecitabine and oxaliplatin was 70.6% (range, 4%–108%) and 74.6 % (range, 0%–100%), respectively. Dose modification and treatment continuation details for each drug are provided in Figure 1.